Skip to content

Topical Sevoflurane for Treatment of Chronic Leg Ulcers

Analgesic and Healing Effect of Topical Sevoflurane for Chronic Venous Ulcers

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05303805
Enrollment
50
Registered
2022-03-31
Start date
2022-05-02
Completion date
2027-01-31
Last updated
2024-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leg Ulcer

Keywords

Leg Ulcer, Sevoflurane, Pain, Healing ulcer, Microbial colonization

Brief summary

Patients with painful non-healing leg ulcer will be enrolled in the clinical single-blinded randomized study. The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment, the control group will only have a standard rinse solution with Cyteal TM (Pierre Fabre Medicament, France). Further treatment will then be carried out in the standard manner. The duration of the study will be 5 days; if the defect heals earlier, it will be terminated early. Exclusion criteria: allergy to sevoflurane, inability to understand the questionnaire Parameters to be monitored will be pain intensity, microbial colonization, appearance and size of the defect

Detailed description

A prospective single-blinded randomized study will be conducted in patients of the Dermatovenereology Clinic of the 3rd Medical Faculty of Charles University (3LF UK) and the University Hospital Kralovske Vinohrady (FNKV) with painful non-healing tibial ulcers. Pain intensity on a numerical rating scale (NRS 0-10) must be NRS\>4. The envelope method will be used for randomization. To blind patients, therapy will be performed by separating patients with a drape from the treatment area of the body. As sevoflurane has a typical odor, it will only be used in the control group to soak up absorbent material held under the distal pole of the wound without skin contact. In the active treatment group, sevoflurane will be applied at the beginning of the wound treatment at approximately 1 ml/cm2 of the ulcer surface. The standard therapy used in the control group will use only Cyteal TM lavage solution, which contains hexamidine diisetione 100 mg in 100 ml, chlorhexidine digluconate 20% solution 100 mg and chlorocresol 300 mg. The primary aim of the study will be pain relief after sevoflurane therapy. Pain intensity will be measured by NRS at 1-hour intervals (excluding sleep); decrease of 2 point for at least 4 hours will be considered significant. Secondary aim will be healing of ulcers. The effect will be controlled by elimination of pathologic microbial colonization, cleaning of the base of the wound and decreasing the size of the ulcer. Microbial colonization will be measured by microbial swab culture before application, after the 1st application before dressing and on the 5th day after application), the appearance of the defect base will be assessed by the appearance of the surface, the size of the defect will be measured in cm2.

Interventions

DRUGSevoflurane

Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.

COMBINATION_PRODUCTCyteal

Rinsing and cleaning of ulcer.

Sponsors

Faculty Hospital Kralovske Vinohrady
CollaboratorOTHER_GOV
Charles University, Czech Republic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Patient will separated by a screen from the treated area. Absorbent material with sevoflurane will be held under the distal pole of the wound to produce a typical smell of sevoflurane.

Intervention model description

The intervention group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment, the control group will only have a standard rinse solution with , with sevoflurane used to soak the absorbent material held under the distal pole of the wound to produce a typical smell of sevoflurane.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with painful (pain intensity on the numerical scale NRS 0-10 is NRS\>4) non- healing tibial venous ulcers

Exclusion criteria

* Allergy to sevoflurane * Inability to understand the pain-intensity questionnaire

Design outcomes

Primary

MeasureTime frameDescription
Pain intensityContinuously for 5 daysPain intensity measured by numeric rating scale (NRS) from 0 - no pain (the best result) to 10 - the worst possible pain using a standard questionnaire

Secondary

MeasureTime frameDescription
Microbial colonizationBefore application of treatment, after the 1st application before tibial coverage and on the 5th day after applicationMicrobial smear for culture
Size of skin defect5 daysMeasured in cm2
Appearance of the ulcer bed5 daysEpithelial tissue, granulation tissue, slough, necrotic tissue

Countries

Czechia

Contacts

Primary ContactJiri Malek, M.D.
malekj@fnkv.cz+4202671622461
Backup ContactJiri Malek, M.D.
malekj@fnkv.cz+4202671622272461

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026